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The analysis of circulating nucleic acids has revealed applications in
the noninvasive diagnosis, monitoring, and prognostication of
many clinical conditions. Circulating fetal-specific sequences have
been detected and constitute a fraction of the total DNA in
maternal plasma. The diagnostic reliability of circulating DNA
analysis depends on the fractional concentration of the targeted
sequence, the analytical sensitivity, and the specificity. The robust
discrimination of single-nucleotide differences between circulating
DNA species is technically challenging and demands the adoption
of highly sensitive and specific analytical systems. We have devel-
oped a method based on single-allele base extension reaction and
MS, which allows for the reliable detection of fetal-specific alleles,
including point mutations and single-nucleotide polymorphisms, in
maternal plasma. The approach was applied to exclude the fetal
inheritance of the four most common Southeast Asian -thalasse-
mia mutations in at-risk pregnancies between weeks 7 and 21 of
gestation. Fetal genotypes were correctly predicted in all cases
studied. Fetal haplotype analysis based on a single-nucleotide
polymorphism linked to the -globin locus, HBB, in maternal
plasma also was achieved. Consequently, noninvasive prenatal
diagnosis in a mother and father carrying identical -thalassemia
mutations was accomplished. These advances will help in cata-
lyzing the clinical applications of fetal nucleic acids in maternal
plasma. This analytical approach also will have implications for
many other applications of circulating nucleic acids in areas such as
oncology and transplantation.
Recently, much interest has been focused on the biology anddiagnostic applications of nucleic acids that are present in
the plasma and serum of humans (1, 2). In particular, fetal DNA
has been found to exist in maternal plasma (3). This discovery
has facilitated the development of noninvasive prenatal diag-
nostic approaches based simply on the analysis of a maternal
blood sample (4). The noninvasive nature of maternal plasma-
based approaches represents a major advantage over conven-
tional methods of prenatal diagnosis, such as amniocentesis and
chorionic villus sampling, which are associated with a small but
finite risk of fetal loss. However, a technical challenge experi-
enced by many workers in the field relates to the ability to
discriminate fetal DNA from the coexisting background of
maternal DNA in maternal plasma. During pregnancy, fetal
DNA amounts to 3–6% of the total DNA in maternal plasma
(5). Hence, the diagnostic reliability of fetal DNA analysis in
maternal plasma depends on the sensitivity and specificity of the
analytical system for the detection of fetal-specific markers.
Fetal SRY and RHD DNA detection from maternal plasma has
reached close to 100% accuracy, as confirmed by many large-
scale evaluations (6–9). The high level of diagnostic accuracy is
attained by the analytical sensitivity contributed by the use of
real-time quantitative PCR (5, 10) and the analytical specificity
conferred by the choice of fetal DNA targets that are absolutely
fetal-specific. The RHD sequence does not exist in the genome
of a rhesus D negative woman. SRY is Y-chromosome specific
and does not exist in the genome of a normal woman. Conse-
quently, the maternal plasma SRY and RHD analyses are rela-
tively free from interference by the background maternal DNA.
However, many fetal genetic diseases are caused by mutations
that result in more subtle genetic differences between the
maternal and fetal DNA sequences in maternal plasma. Such
fetal diseases may potentially be diagnosed noninvasively by
means of the detection or exclusion of the paternally inherited
mutant allele in maternal plasma. The development of robust
assays for the discrimination of less dramatic differences be-
tween fetal and maternal DNA in maternal plasma has been
technically challenging (11). Therefore, despite many potential
applications reported for fetal mutation detection in maternal
plasma, such as achondroplasia, Huntington’s disease, cystic
fibrosis, and hemoglobin E (11–15), most published data involve
case reports of isolated patients. Large-scale evaluation of
analytical protocols for circulating fetal DNA discrimination has
been limited. Reliable discrimination between the fetal and
maternal DNA sequences would depend heavily on the analyt-
ical specificity of the assay system. The degree of analytical
specificity required for accurate analysis is inversely related to
the degree of genetic difference between the alleles of interest
and the background DNA (16).
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We have previously evaluated the reliability of a mutation-
specific real-time PCR assay for maternal plasma detection of
the most common Southeast Asian -thalassemia mutation,
which involves the deletion of four nucleotides (CTTT) at
codons 41 and 42 [CD 4142 (-CTTT)] of the -globin gene,
HBB (17). Maternal plasma is analyzed with the aim of reliably
confirming or excluding the presence of the CD 4142 (-CTTT)
mutation in pregnancies in which the father is a carrier for the
mutation. Because the manifestation of -thalassemia major
depends on the coinheritance of both the maternal and paternal
mutations, the negative detection of the paternal mutation in
maternal plasma would effectively infer that the fetus has
inherited the nonmutant paternal allele, and, thus, -thalassemia
major could be excluded. Such a prenatal diagnostic approach
depends on the absolute sensitivity and specificity of the assay
system. In this study, analytical specificity conferred by the
design of allele-specific primers against the 4-nt deletion was
coupled with the assay sensitivity contributed by real-time PCR
analysis.
Compared with the detection of the 4-bp deletion mentioned
above, the reliable discrimination of single-nucleotide differ-
ences between circulating DNA species has posed additional
technical difficulty (11). The subtlety of single-base differences
requires analytical systems with an even higher degree of allele
specificity (16). More than 200 -thalassemia mutations have
been described, many of which are point mutations (18). In an
attempt to extend the noninvasive prenatal diagnostic approach
to pregnancies involving other -thalassemia mutations, we
evaluated the real-time PCR approach for fetal point mutation
detection in maternal plasma. This approach has proven to be
difficult (unpublished data) because of the lack of absolute
specificity of allele-specific primers (11), compounded by the low
fractional concentration of fetal DNA in maternal plasma (5).
Analytical sensitivity could only be improved at the expense of
specificity and vice versa (11). In the present study, we evaluated
the use of MS for the discrimination of fetal point mutations in
maternal plasma and developed an approach for the reliable
exclusion of -thalassemia mutations in maternal plasma. We
further evaluated the approach for the noninvasive prenatal
diagnosis of a mother and father sharing an identical -thalas-
semia mutation, a concurrence previously perceived as a chal-
lenge for maternal plasma-based prenatal diagnosis for autoso-
mal recessive diseases.
Materials and Methods
Patient Recruitment and Sample Collection. Twelve pregnancies at
risk for -thalassemia major were recruited with informed
consent and institutional ethics approval from established pre-
natal diagnostic centers in Hong Kong, Thailand, Singapore, and
Malaysia. Fifty pregnant women seeking second-trimester an-
euploidy prenatal diagnosis with subsequent confirmation of a
normal fetal karyotype also were recruited. Ten milliliters of
maternal and paternal blood was collected into EDTA tubes
before amniocentesis, chorionic villus sampling, and cordocen-
tesis. Three milliliters of amniotic f luid also was collected from
the normal pregnancies and stored at 4°C until analysis. Parental
and fetal genotypes were determined according to established
diagnostic practices (19, 20). Maternal plasma was harvested by
a two-step centrifugation protocol comprised of 10-min centrif-
ugation at 1,600  g, followed by 10-min centrifugation at
16,000  g (21). Maternal plasma DNA was extracted with the
QIAamp Blood Kit (Qiagen, Valencia, CA) by following the
‘‘blood and body fluid protocol,’’ according to the manufactur-
er’s recommendations. To each column, 800 l of plasma
was applied and eluted into 50 l of distilled deionized H2O. The
plasma DNA samples were stored at 20°C until analysis by a
central laboratory.
Maternal Plasma Analysis. Paternal allele detection in maternal
plasma was performed by using the MassARRAY system (Se-
quenom). The MassARRAY system is a matrix-assisted laser
desorption ionizationtime-of-f light MS system designed for the
detection of primer-extended PCR products (22). The maternal
plasma MS analyses were performed blindly without knowledge
of the fetal genotype. Two analytical protocols were evaluated,
including the standard Homogenous MassEXTEND protocol
provided by Sequenom and a newly developed protocol, termed
single allele base extension reaction (SABER) (Fig. 1). Both
protocols involved PCR amplification of the paternally inherited
fetal allele and the maternal background alleles from maternal
plasma, followed by a base extension reaction before MS anal-
ysis. The SABER protocol involves a different base extension
step, which is restricted to the allele of interest, and confers
theoretical improvements in the detection sensitivity (see
below).
PCR Amplification. All DNA oligonucleotides were purchased
from Integrated DNA Technologies (Coralville, IA). HotStar
Fig. 1. Schematic illustration of the SABER and standard MassARRAY assays.
Maternal plasma detection of the paternally inherited fetal-specific -thalas-
semia mutation, IVS2 654 C 3 T, is presented as an illustrative example.
Maternal plasma is first amplified by PCR. The PCR products are subjected to
base extension by the standard and SABER protocols. The standard protocol
involves the base extension of both the mutant fetal allele (T allele) and the
background allele (C allele), whereas the SABER method only extends the
fetal-specific mutant allele. The base extension reactions are terminated by
dideoxynucleotides, indicated in boxes. The extension products of the stan-
dard protocol include a predominance of the nonmutant allele (open arrows)
with a small fraction of the fetal-specific mutant allele (filled arrows). The low
abundance of the fetal allele (filled peak) is overshadowed by the nonmutant
allele (open peak) on the mass spectrum. Because SABER only involves the
extension of the mutant allele, the latter’s presence (filled peak) can be
robustly identified from the mass spectrum. The striped peaks represent the
unextended primer.
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Taq Polymerase (Qiagen) was used for all PCRs. Five microliters
of plasma DNA was added to each 10-l PCR. PCR primers
(Table 1) were used at a 200 nM final concentration. The PCR
condition was 95°C for 15 min for hot start, followed by
denaturing at 94°C for 20 sec, annealing at 56°C for 30 sec,
extension at 72°C for 1 min for 45 cycles, and final incubation at
72°C for 3 min. Five microliters of PCR products was treated
with shrimp alkaline phosphatase (Sequenom) for 20 min at
37°C to remove excess dNTPs, as described in ref. 23.
Standard Base Extension and SABER. Thermosequenase (Seque-
nom) was used for the base extension reactions. In the standard
protocol, conventional base extension was carried out whereby
both alleles interrogated by the base extension primer were
extended by adding a mixture of 2,3-dideoxynucleoside triphos-
phates and dNTPs (Table 1 and Fig. 1). In contrast, primer
extension in the SABER protocol was restricted to the fetal-
specific allele of interest by the addition of a single species
of dideoxynucleoside triphosphate without any dNTP (Table 1
and Fig. 1). Five microliters of PCR products was used in 9-l
reactions in both protocols. The reaction condition was 94°C for
2 min, followed by 94°C for 5 sec, 52°C for 5 sec, and 72°C for
5 sec for 40 cycles. All reactions were carried out in a GeneAmp
PCR system 9700 thermal cycler (Applied Biosystems). The final
base extension products were analyzed by MS as described in ref.
23. Briefly, the final base extension products were treated with
the SpectroCLEAN (Sequenom) resin to remove salts in the
reaction buffer. We dispensed 10 nl of reaction solution onto
a 384-format SpectroCHIP (Sequenom) prespotted with a ma-
trix of 3-hydroxypicolinic acid by using a SpectroPoint (Seque-
nom) nanodispenser. A modified Biflex matrix-assisted laser
desorption ionizationtime-of-f light MS (Bruker, Billerica, MA)
was used for data acquisitions from the SpectroCHIP. The
expected molecular weights of all relevant peaks were calculated
before the analysis and identified from the mass spectrum. All
analyses were performed in triplicate.
Fetal-Specific Single-Nucleotide Polymorphism (SNP) Detection from
Maternal Plasma. The feasibility of using the MassARRAY
system to discriminate and detect single-nucleotide differences
between fetal and maternal DNA in maternal plasma was first
assessed by the detection of paternally inherited SNPs. The
maternal and fetal genotypes for 11 SNPs on chromosome 11p
were determined in normal pregnancies by using maternal
genomic DNA and amniotic f luid samples. The most informative
SNP, rs2187610 (SNP database, www.ncbi.nlm.nih.gov), was
selected for further analysis. This SNP is located 1.3 kb down-
stream of the HBB locus.
Fetal-Specific -Thalassemia Mutation Detection from Maternal
Plasma. MassARRAY assays (Table 1) were designed for ma-
ternal plasma analysis of the four most common -thalassemia
mutations in Southeast Asia, CD 4142 -CTTT, IVS2 654 (C3
T), nt 28 (A 3 G), and CD 17 (A 3 T) (24, 25). Paternal
mutation detection in maternal plasma was determined by using
both protocols. For each sample, the mutation-specific assay was
selected according to the mutation that the father carried.
Fetal Haplotype Detection from Maternal Plasma. The parental
genotypes at the SNP locus, rs2187610, were determined for the
pregnancies at risk for -thalassemia major. For parents who
were found to be informative for the SNP, the linkage between
the paternal HBB mutant with the SNP alleles at rs2187610 was
determined. Haplotype analysis was determined by using a
method on parental genomic DNA described in ref. 23. The
ability to detect the paternal SNP linked to the mutant HBB
allele in maternal plasma was determined by using the SABER
protocol.
Results
Fetal-Specific SNP Allele Discrimination in Maternal Plasma. The SNP
rs2187610 is a CG polymorphism. Among the 50 normal
pregnancies, 16 pregnant women had the CC genotype. The fetal
genotypes were CC and GC in 10 and 6 of these pregnancies,
respectively. MassARRAY assays were designed to detect the
paternally inherited fetal-specific G allele in maternal plasma
(Table 1). The presence or absence of the G allele in maternal
plasma was concordant between the standard and SABER
Table 1. PCR and extension primer sequences
Mutation CD 4142 (-CTTT) IVS2 654 (C3 T) nt 28 (A3 G) CD 17 (A3 T) rs2187610
PCR primer 1 5-ACGTTGGATGT-
AACAGCATCA-
GGAGTGGAC-3
5-ACGTTGGATG-
TAACAGTGAT-
AATTTCTGGG-3
5-ACGTTGGATG-
TAGGGTTGGC-
CAATCTACTC-3
5-ACGTTGGATG-
TCACCACCAA-
CTTCATCCAC-3
5-ACGTTGGATG-
ATGCCATTTC-
ATGGTTACC-3
PCR primer 2 5-ACGTTGGATG-
CTATTTTCCCA-
CCCTTAGGC-3
5-ACGTTGGATGG-
AAACCTCTTAC-
ATCAGTTAC-3
5-ACGTTGGATG-
AGCAATAGAT-
GGCTCTGCCC-3
5-ACGTTGGATG-
TCAAACAGAC-
ACCATGGTGC-3
5-ACGTTGGATG-
GAAGTGAGGC-
TACATCAAAC-3
Standard protocol
Extension primer 5-GATCCCCAAA-
GGACTCAA-3
5-TGATAATTTCT-
GGGTTAAGG-3
5-AGCCAGGGCT-
GGGCATA-3
5-TTCATCCACGT-
TCACCT-3
5-ACCTTTCATTTG-
TTCATTGTTTT-3
Terminator mix* CGT AC AC CGT ACT
Expected molecular weight
of extended nonmutant allele
6,088 6,475 5,558 5,345 7,225 (G allele)
Expected molecular weight
of extended mutant allele
5,735 6,804 5,887 5,683 7,569 (C allele)
SABER protocol
Extension primer 5-GATCCCCAAA-
GGACTCAA-3
5-ATATGCAGAAA-
TATTGCTATT-3
5-GATGGCTCTG-
CCCTGACTT-3
5-TTACTGCCCT-
GTGGGGC-3
5-ACCTTTCATTTG-
TTCATTGTTTT-3
Terminator ddCTP ddATP ddCTP ddTTP ddCTP
Expected molecular weight
of nonextended primer
5,462 6,443 5,771 5,193 6,952
Expected molecular weight
of extended allele
5,735 6,741 6,044 5,482 7,225 (G allele)
*CGT mix is ddCTPddGTPddTTPdATP in which dd indicates the 2,3-dideoxynucleoside. Similarly, AC mix is ddATPddCTPdGTPdTTP.
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protocols, and these results were completely concordant with
amniotic f luid analyses.
Paternally Inherited -Thalassemia Point Mutation Detection and
Exclusion in Maternal Plasma. Among the 12 recruited pregnancies
at risk for -thalassemia major, 11 pregnancies involved couples
in which the father and mother carried different -thalassemia
mutations (Table 2). Assays were designed to interrogate the
four -thalassemia mutations in maternal plasma, three of which
were point mutations. The results are shown in Table 2. Detec-
tion of the paternal mutation in maternal plasma by using the
SABER protocol was completely concordant with the fetal
genotype determined by amniotic f luid, chorionic villus, or fetal
blood analyses, whereas the standard protocol revealed two
false-negative results (cases 5 and 9). Representative MS tracings
for the analyses are shown in Fig. 2.
Noninvasive Fetal Haplotyping. SNP analysis for the at-risk preg-
nancies revealed three informative couples (cases 3, 11, and 12),
including the parents sharing an identical -thalassemia muta-
tion, whereby the maternal and paternal SNP genotypes were
nonidentical. Results of the haplotype analysis are shown in
Table 3. The paternal mutant allele was linked to the G allele at
rs2187610 for the three cases. Maternal plasma analysis for the
paternal G allele was completely concordant with the expected
fetal genotype.
Discussion
The reliable discrimination of subtle (e.g., single base) differ-
ences between fetal and maternal DNA in maternal plasma has
hitherto been a technical challenge (11). In this study, we took
advantage of the analytical specificity conferred by a base
extension reaction and the sensitivity of MS analysis. The
SABER protocol is theoretically more sensitive than the stan-
dard protocol. First, in contrast to the standard protocol in which
all relevant alleles are used as the templates for the base
extension reaction, SABER involves the extension of a single
nucleotide for the allele of interest only (Fig. 1). Thus, for fetal
DNA analysis in maternal plasma, the SABER assays were
designed so that the base extension is devoted only to the
extension of the fetal-specific allele for the single discriminatory
nucleotide from the maternal one. Furthermore, the matrix-
assisted laser desorption ionizationtime-of-f light MS has a
Table 2. Detection of paternally inherited HBB mutations in maternal plasma
Case
HBB mutation Maternal plasma analysis
Fetal
genotype†
Weeks
gestation
CD 4142
(-CTTT)
IVS2 654
(C3 T)
nt 28
(A3 G)
CD 17
(A3 T)
Standard
protocol SABER
1 F M — — Neg Neg ** 11
2 — F — M Neg Neg ** 18
3 F — — M Neg Neg ** 21
4 M F — — Pos Pos F* 18
5 M — F — Neg Pos FM 17
6 F M — — Pos Pos F* 11
7 F M — — Pos Pos F* 14
8 F — — — Neg Neg ** 7
9 — — — F Neg Pos F* 12
10 M F — — Neg Neg ** 17
11 F — — — Pos Pos F* 20
12 M & F — — — N.A. N.A. ** 18
All of the parents are carriers for -thalassemia and have one HBB mutation. The maternal mutation is not indicated for cases where
the maternal mutation is not one of the four HBB mutations studied. F and M, mutations of the father and mother, respectively; —, no
mutation; Neg, negative; Pos, positive; N.A., not applicable.
†The fetal genotype determined by conventional methods is indicated by the inheritance of the paternal mutation F, the maternal
mutation M, or the normal allele, *.
Fig. 2. MS analyses of the paternally inherited -thalassemia IVS2 654
mutation in maternal plasma. For all mass spectra, mass (x axis) represents the
molecular weight of the marked peaks. The expected molecular weights of all
relevant peaks were calculated before the analysis. Intensity (y axis) is in
arbitrary units. P and PP, unextended primer and pausing product (i.e., pre-
mature termination of the base extension reaction or incorporation of an
undigested dGTP from shrimp alkaline phosphatase treatment for the wild-
type DNA template), respectively. A and B illustrate the mass spectra obtained
by the standard MassARRAY protocol for a fetus negative and positive for the
mutation, respectively. T, expected mass of the mutant allele; C, position of
the alleles without the IVS2 654 mutation. C and D illustrate the mass spectra
obtained by the SABER MassARRAY protocol for a fetus negative and positive
for the mutation, respectively. IVS2 654, expected mass of the mutant allele.
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dynamic range of 100-fold. Because the paternal-specific fetal
allele exists at 3–6% in total maternal plasma DNA, its
corresponding peak in the mass spectrum is often dwarfed by the
background peak when analyzed by the standard protocol (Figs.
1 and 2). On the contrary, the SABER method only extends the
intended paternal-specific fetal allele so that the background
allele peak is not produced, resulting in more robust detection
(Figs. 1 and 2). The theoretical advantages of SABER over the
standard method are realized in our analyses as evident by the
false-negative results for the latter protocol.
The reliability of the SABER assays for single-nucleotide
discrimination between circulating fetal and maternal DNA has
been illustrated by the maternal plasma detection of fetal
-thalassemia point mutations and SNPs. The ability to robustly
analyze fetal-specific SNPs in maternal plasma is a useful adjunct
procedure for maternal-plasma fetal DNA analysis as a safe-
guard against the possibility of false-negative detection due to
fetal DNA degradation, DNA extraction failures, or PCR allele
dropout. Such a safeguard mechanism has been advocated
by several workers in the routine performance of maternal
plasma analysis for the noninvasive prenatal assessment of
fetal rhesus D status (26–28). Initially, the detection of Y-
chromosome sequences in maternal plasma had been adopted to
confirm cases that tested negative for RHD (7, 26). Because of
the inherent restriction of Y-chromosome detection to only male
fetuses, fetal-specific internal controls based on panels of inser-
tiondeletion polymorphisms had been developed (28). The
adoption of the insertiondeletion panel reflects the lack of
robust methods for fetal SNP detection in the past. Hence, with
the availability of a reliable MS method for fetal SNP detection
in maternal plasma, the number of potential gender-independent
internal control targets for circulating fetal DNA detection has
increased substantially.
A more important implication of the ability to analyze circu-
lating fetal SNPs lies in its immediate relevance to fetal haplo-
type analysis from maternal plasma. Noninvasive fetal haplo-
typing could be achieved by means of analyzing polymorphisms
linked to a mutated locus. As demonstrated in case 12, haplotype
analysis between the HBB locus and a linked polymorphism
allowed the noninvasive prenatal exclusion of -thalassemia
major, despite the presence of the same HBB mutation in both
parents. This procedure overcomes a previously perceived chal-
lenge in maternal plasma-based prenatal diagnosis of autosomal
recessive diseases that limited its applicability to couples sharing
different mutations (17). The haplotype approach also could be
applied to maternal plasma detection of a fetal SNP allele linked
to the paternal nonmutant allele. The positive detection of such
an allele would allow for the positive prenatal exclusion of
-thalassemia major noninvasively (29, 30).
Further work is needed to evaluate additional SNP markers
surrounding the HBB locus. A SNP panel could be assembled so
that the noninvasive prenatal diagnosis could be applied to a
larger proportion of pregnancies at risk for -thalassemia. The
four mutations investigated in this study account for 90% of all
-thalassemia mutations in Southeast Asia (24, 25). The present
approach could be applied to all pregnancies in which the father
is a carrier of one of the four mutations and thus has much
potential for routine adoption. An invasive prenatal diagnostic
procedure could be avoided in 50% of these pregnancies in which
the lack of inheritance of the paternal mutation by the fetus is
confirmed by maternal plasma analysis. A large-scale evaluation
is needed.
This study presents exciting technological advancements in cir-
culating fetal DNA analysis. A robust system for single-
nucleotide discrimination among circulating DNA species has
been developed. The MassARRAY approach is automatable
with a capacity to analyze 2,000 samples per day in triplicate,
thus making the system practical for routine use. The MS system
is potentially applicable to many other areas of fetal DNA
detection, namely the prenatal diagnosis of other single-gene
disorders and the quantification of fetal DNA in maternal
plasma (31). Quantitative aberrations in circulating fetal DNA
concentrations have been demonstrated for fetal chromosomal
aneuploidies (32, 33), preeclampsia (34, 35), preterm labor (36),
and many other pregnancy-associated complications. Quantita-
tive analysis of circulating fetal DNA has been reliant on the
detection of Y-chromosome sequences because of the lack of
gender-independent fetal-specific markers. However, this hurdle
can potentially be overcome by the immediate adoption of MS
quantification of fetal SNPs in maternal plasma. Both the MS
approach and the gender-independent fetal SNP assays could be
extended to the study of fetal DNA in other maternal bodily
f luids such as urine (37) and cerebrospinal f luid (38) or the
phenomenon of cellular microchimerism (39–41), all of which
also have been previously studied by means of the detection of
Y-chromosome sequences (42, 43).
Besides fetal DNA sequences, the MS SABER approach
could be extended to other areas of circulating nucleic acid
analysis, including circulating tumor-specific DNA, such as
Epstein–Barr virus DNA in nasopharyngeal carcinoma patients
(44), KRAS point mutations (45, 46), and donor-specific DNA in
transplant recipients (47). Therefore, we believe that MS will
play an increasingly important role in the future research and
application of circulating nucleic acids.
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Table 3. Haplotype analysis of paternally inherited alleles in maternal plasma
Case
Genotype for SNP
rs2187610 Paternal haplotype analysis†
Maternal plasma SABER
analysis
Fetal HBB
genotype‡Mother Father
HBB mutant
allele
HBB wild-type
allele SNP G allele
Paternal HBB
mutation
3 CC GC G C Neg Neg **
11 CC GC G C Pos Pos F*
12 CC GC G C Neg N.A. **
Neg, negative; Pos, positive; N.A., not applicable.
†G and C denote the rs2187610 allele linked to the mutant or wild-type paternal HBB alleles, respectively.
‡The fetal genotype determined by conventional methods is indicated by the inheritance of the paternal mutation F, the maternal
mutation M, or the normal allele, *.
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